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G protein coupled receptors (GPCRs) are one of the major classes of cell surface recep-
tors and are associated with a group of G proteins consisting of three subunits termed
alpha, beta, and gamma. G proteins are classified into four families according to their α
subunit; Gαi, Gαs, Gα12/13, and Gαq. There are several downstream pathways of Gαq of
which the best known is upon activation via guanosine triphosphate (GTP), Gαq activates
phospholipase Cβ, hydrolyzing phosphatidylinositol 4,5-biphosphate into diacylglycerol and
inositol triphosphate and activating protein kinase C and increasing calcium efflux from the
endoplasmic reticulum. Although G proteins, in particular, the Gαq/11 are central elements
in GPCR signaling, their actual roles have not yet been thoroughly investigated.The lack of
research of the role on Gαq/11 in cell biology is partially due to the obscure nature of the
available pharmacological agents. YM-254890 is the most useful Gαq-selective inhibitor
with antiplatelet, antithrombotic, and thrombolytic effects. YM-254890 inhibits Gαq signal-
ing pathways by preventing the exchange of guanosine diphosphate for GTP. UBO-QIC is
a structurally similar compound to YM-254890, which can inhibit platelet aggregation and
cause vasorelaxation in rats. Many agents are available for the study of signaling down-
stream of Gαq/11. The role of G proteins could potentially represent a novel therapeutic
target. This review will explore the range of pharmacological and molecular tools available
for the study of the role of Gαq/11 in GPCR signaling.
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INTRODUCTION
G protein coupled receptors (GPCRs) constitute the largest class of
cell surface receptors. GPCR genes account for 5% of the human
genome (1, 2). Of these receptors, all are seven membrane span-
ning receptors but not all are G protein binding but it is convenient
to refer to the receptors as GPCRs. GPCRs also represent the largest
and among the most efficacious class of therapeutic targets for
diseases including cardiovascular disease, cancer, and asthma (1,
2). Many drugs have been developed based on GPCRs and these
include some of the most important agents in human medicine, for
example, in the treatment of asthma and hypertension (3). GPCRs
are helical transmembrane receptors complemented by functional
extracellular and intracellular loops (4). Within the GPCR super-
family, there have been five major families identified. They are the
rhodopsin, secretin, glutamate, adhesion and frizzled/taste2 fami-
lies (5). Most GPCRs contain seven helices and three intracellular
loops; however, some members of the rhodopsin family may have
eight helices and four intracellular loops (6). GPCRs bind hor-
mones, neurotransmitters, or growth factors (7), which initiate a
plethora of cellular responses. GPCRs are generally ligand acti-
vated but they can also bind to Gα-subunits in the absence of a
ligand, a phenomenon known as receptor pre-coupling. GPCRs
interact with their respective G proteins only upon receptor acti-
vation known as the collision coupling model or in the absence of
agonist known as the pre-coupled receptor model (8).
Whereas protein tyrosine and serine/threonine kinase recep-
tors have intrinsic catalytic activity, GPCRs do not have enzymatic
activity per se but are linked to Gα proteins, which are GTPases,
and mediate the signal transduction (9). G proteins of the α, β,
and γ families provide the specificity and functionality of GPCRs.
G proteins are classified into four families according to their α
subunit: Gi, Gs, G12/13, and Gq (Figure 1). The Gs and Gi families
regulate adenylyl cyclase activity, while Gq activates phospholi-
pase Cβ and G12/13 can activate small GTPase families (10). The
Gq family consists of four members: Gq, G11, G14, and G15/16 (11,
12) and their respective α subunits are thus Gαq, Gα11, Gα14, and
Gα15/16 (Figure 1).
The role of G proteins in GPCR signaling has not been as inten-
sively investigated as other aspects of GPCR signaling possibly due
to the limited availability of convenient pharmacological tools.
The most useful pharmacological agent has been the compound
known as YM-254890, which is a cyclic depsipeptide isolated from
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FIGURE 1 | Classification of G proteins into four families according to
their α subunit. The Gα subunit is made up of Gαs, Gαi, Gαq/11, and
Gα12/13. Gαs and Gαi families regulate adenylyl cyclase activity, while Gαq
activates PLC-β and the Gα12/13 can activate small GTPase families. The Gαq
subunit is made up of four members, which include the Gαq, Gαq/11, Gαq/14,
and Gαq15/16.
the Chromobacterium sp. Initial studies indicated that this is a spe-
cific inhibitor of Gαq/11. YM-254890 has had variable availability
and has not been available in recent times. As the importance of
GPCR signaling in physiology and pathophysiology continues to
grow, the potential importance of G proteins increases both for
the fundamental cell biology and as potential therapeutic targets.
One of the major and expanding areas of GPCR signal-
ing is transactivation-dependent signaling (13) in which GPCRs
transactivate protein tyrosine kinase (PTK) and protein ser-
ine/threonine kinase receptors (14–16). Transactivation greatly
expands the roles of GPCRs in cell biology (13, 17–19). GPCR
transactivation of PTK receptors was discovered in 1996, has been
the subject of almost 200 publications, and has been recently
reviewed (20). Our laboratory has recently extended the paradigm
of GPCR to PTK receptor transactivation to include the transacti-
vation of protein serine/threonine kinase receptors and specifically
the protease-activated receptor (PAR)-1 and endothelin receptor
(ETR)-mediated transactivation of the transforming growth fac-
tor (TGF)-β type I receptor (TGFBR1) also known as Activin-like
Kinase (Alk)-V (15, 16, 21). There is very little information on the
role of Gα proteins in GPCR transactivation signaling. There is
a need for synthetic programs to provide new molecules with the
pharmacological properties of YM-254890 and such programs will
provide agents, which allow for a much broader range of studies on
the role of G proteins in GPCR signaling. This review focuses on
the role of Gαq/11 in GPCR signaling in the context that the avail-
ability of new tools will shortly lead to a large increase in studies
in this area. The two targets of compound such as YM-254890 are
Gαq and Gα11 – these two proteins are distinct gene products but
they have an identical number of amino acids and essentially iden-
tical structures and functions. In this review, we refer to Gαq but
most statements will also relate to Gα11 and only where differences
are known and of significance will this distinction be drawn.
Gαq/11 SIGNALING
The responses to GPCR agonists and the conformational changes
in the GPCR that are induced by ligand binding are transduced
and then mediated by heterotrimeric G protein complexes. Con-
sisting of three subunits α, β, and γ, their role is to transduce
external stimuli into intracellular signaling cascades. Most of the
specificity of signaling resides in the Gα subunit. In an inacti-
vated state, the α subunit binds guanosine diphosphate (GDP);
however, upon binding activation of the GPCR, GTPase activity is
induced and promotes the exchange of bound GDP for guanosine
triphosphate (GTP). The α subunit and βγ complex then dissoci-
ate from one another and interact with their associated effectors
(22). In the most common signaling pathways, Gαq activates
phospholipase Cβ (PLCβ), which hydrolyzes phosphatidylinositol
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4,5-bisphosphate (PIP2) releasing diacylglycerol (DAG) and 1,4,5-
inositol trisphosphate (IP3). DAG activates a number of isoforms
of protein kinase C (PKC), whereas IP3 diffuses to the endoplasmic
reticulum (ER) and binds to IP3 receptors on ligand-gated calcium
channels on the surface of the ER leading to a massive release of
calcium ions into the cytosol and subsequently in some cells, the
opening of cell surface calcium channels leading to the influx of
extracellular calcium (23). The calcium cycle continues with the
uptake of calcium back into the ER by Ca ATPases.
In addition to this paradigm, it has been shown that RhoA
is a mediator of calcium sensitization and is downstream of Gα
signaling. Activation of the members of the Rho family is via
GTP binding. The exchange of GDP for GTP on these proteins is
controlled through guanine nucleotide exchange factors (GEFs),
which catalyze the exchange of GDP for GTP (24). Activation of
Rho-mediated signaling pathways can be indirectly mediated by
GPCRs, integrins, or receptor tyrosine kinases. G proteins, Gα12
and Gα13, activate Rho by activation of a Rho GEF (25). It is
only when RhoA is active that it can interact with and activate
downstream effectors such as Rho kinase (ROCK).
Thrombin activation of PAR-1 involves both Gαq/11 and
Gα12/13, which causes RhoA activation signaling downstream to
stimulate ROCK and PKC-related kinase. RhoA activation coupled
to Gαq/11 involves intracellular release of calcium involving the
downstream activation of the two Rho-regulated protein kinases,
which in turn regulates the contraction of actomysin and the
formation of focal adherence in human endothelial cells. In the
case of Gα12/13, RhoA is activated through GEFs such as p115
RhoGEF, PDZ-RhoGEF, or leukemia-associated RhoGEF. In the
case of Gαq/11, it is suggested that the GEFs utilized may involve
p63 Rho GEF or Trio; however, the specific GEFs involved in this
signaling pathway are yet to be confirmed.
Overexpression of active Gα11 or stimulation of the m1 mus-
carinic acetylcholine receptor induces apoptosis in HeLa cells. Rho
kinase and ROCK are stimulated due to the cleavage of activated
caspase 3 during apoptosis. There have been several studies on the
mechanisms involved in Gαq/11-induced apoptosis, which show
that this phenomenon is cell- and context-dependent. In COS-7
and CHO cells, Gαq-induced apoptosis is dependent on PKC, and
angiotensin II-induced myocyte apoptosis is dependent on the
release of intracellular calcium suggesting the involvement of PLC
pathway.The molecular mechanism of Gαq/11 induced apoptosis
leading to the activation of Rho/ROCK is not clearly understood;
however, some studies have shown that Gαq/11 signaling activated
RhoA, which inhibited insulin-stimulated Akt phosphorylation in
HeLa cells. In CHO cells, Gαq and Gα11 regulate actin cytoskele-
ton remodeling through the activation of ADP-ribosylation factor
6. Platelets stimulated with P2Y1 agonist leads to the activation
of RhoA, this activation was inhibited by Gαq inhibitor YM-
254890, indicating that RhoA activation downstream of purinergic
(P2Y)-1 receptors requires Gαq stimulation (26).
STRUCTURE OF Gαq
Gαq and Gα11 are distinct gene products but from the same chro-
mosome (12). These two proteins have an identical number of
amino acids and are functionally almost identical. However, the
tissue distribution of the two isoforms is distinct (12). Gαq is a 359
amino acid protein comprising two domains: a helical domain and
a GTPase binding domain. The GTPase domain is responsible for
hydrolyzing GTP to GDP, as well as binding the Gβγ subunits,
GPCRs, and other effectors. This domain is conserved between all
members of the G protein superfamily (6). The GTPase domain
contains three switch regions, which are flexible loops that change
conformation when bound with GTP. The helical domain contains
six α-helices, which encapsulates nucleotides in the protein core
by forming a lid over the nucleotide-binding pocket. Of all G pro-
tein families identified, members of the Gαq family share the most
amino acid sequence homology. In humans, Gα11, Gα14, and Gα16
share 90, 80, and 57% sequence similarities, respectively (27).
FUNCTIONS OF Gαq
Gαq plays a role in platelet aggregation. Bleeding time and
resistance to thromboembolism are dramatically increased in
Gαq-deficient mice compared to wild type (28). Gαq is also
implicated in insulin-stimulated glucose transport (29). In 3T3–
L1 adipocytes, Gαq is required for insulin-induced GLUT4
translocation and the stimulation of 2-deoxy-d-glucose uptake.
Angiotensin II dose-dependently increases cell proliferation in
smooth muscle cells and this is inhibited by the Gαq antago-
nist, GP-2A (30). Gαq/11 proteins are involved in HIV-1 envelope
glycoprotein-dependent cell–cell fusion upstream of Rac-1 (31).
Genetically modified mice studies suggest that receptors coupled
to the Gαq play a role in the development of heart failure (32).
Following treatment to activate Gαq in transgenic mice expressing
a silent Gαq, the mice rapidly developed a dilated cardiomyopathy
and heart failure. Transgenic mice expressing an inducible Gαq
that cannot activate PLCβ do not develop heart failure. Thus, the
activation of Gαq resulting in heart failure requires the activation
of PLCβ (32).
ROLE OF Gαq IN THE GPCR TRANSACTIVATION OF KINASE
RECEPTORS
There are now two major pathways of GPCR to cell surface recep-
tor kinase transactivation – the well-established transactivation of
PTK receptors, notably epidermal growth factor receptor (EGFR)
and the recently identified transactivation of serine/threonine
kinase receptors, specifically the TGFBR1 (14–16, 33). There is
some information of the role of Gα proteins and thus Gαq in
the transactivation of PTK receptors but nothing is known of
the role of Gαq in the transactivation of serine/threonine kinase
receptors.
G protein coupled receptors coupled to Gαq, such as bombesin
receptor or Gαi proteins, such as M2 muscarinic acetylcholine
receptor, expressed in COS-7 cells show increased EGFR tyro-
sine phosphorylation more than that resulting from Gαi coupled
receptor stimulation. Cells transfected with Gαq-coupled GPCRs
are unaffected by pertussis toxin while Gαi coupled receptors
are, as expected, blocked by pertussis toxin treatment (34). Thus,
EGFR transactivation may occur through both pertussis toxin-
sensitive and -insensitive pathways. GPCR transactivation of ser-
ine/threonine kinase receptors and specifically TGFBR1 by both
ETR and PAR-1 has been identified in vascular smooth muscle
cells (VSMCs) but the role of Gαq in transactivation of TGFBR1
has not been reported (15, 16, 21).
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Thus far, the biochemical mechanisms of GPCR to protein
tyrosine and protein serine/threonine kinase receptors have been
found to be completely distinct with, for example, the former
involving MMPs and the latter being independent of MMPs (16).
The transactivation of serine/threonine kinase but not tyrosine
kinases involves the cytoskeleton (16). The independent signal-
ing pathways have made it difficult to envisage a single potential
therapeutic target for the inhibition of all GPCR transactivation
signaling (18).
It will be interesting to investigate the role of Gαq proteins
in tyrosine and serine/threonine kinase transactivation signal-
ing as it has the potential to be a point of commonality in
GPCR-mediated transactivation of cell surface protein tyrosine
and serine/threonine kinase receptor signaling.
MOLECULAR AND PHARMACOLOGICAL REGULATION OF G
PROTEINS
G proteins in cells can be effectively knocked down utilizing a
molecular approach and this has allowed for detailed studies of
the function of various G proteins and their interactions. Classic
experimental approaches assume that the intervention is specific
and does not alter other parameters that would impact on the
experimental result of the index intervention. This is not always
the situation and is certainly not the reliable paradigm in the
case of the regulation of G proteins. Gilman and colleagues (35)
demonstrated that knocking down Gβ proteins resulted in a com-
pensatory increase in both the effector, adenylyl cyclase and even
the GPCR, being the β2-adrenergic receptor. Results of knock
down interventions are also not always reciprocal – the knock
down of one G protein may lead to a compensatory increase in
another G protein family member but the reverse or reciprocal
phenomenon may not occur (35). Thus, the knock down of Gαq
and Gα11 in HeLa cells increased the accumulation of Gαi and
Gα0 but the reciprocal response did not occur (35).
Gα and β proteins exist in approximately equal mass stoichiom-
etry in most cells. This occurs primarily because Gβ proteins sta-
bilize bound Gα proteins with the corollary that free Gα proteins
are degraded. However, Gα proteins are subject to palmitylation
and myristoylation and these processes may bind Gα proteins
to the cell membrane and stabilize the proteins (36). A conse-
quence of the role of post-translational regulation on stability and
the cellular levels of G proteins is that the relationship between
mRNA and protein levels may be perturbed. Higher mRNA lev-
els may lead to increased expression of the G protein, but if it
is orphaned and free the protein may be degraded providing
for high level of mRNA and in the presence of low levels of
protein.
Molecular approaches to the up- and down-regulation of target
proteins are a major component of modern mechanistic studies
of cell biology. However, as exemplified above, alteration of target
protein levels may result in compensatory changes in other com-
ponents of a system and the perturbation might not provide the
expected result. Pharmacological approaches nullify the activity
or function of a target protein without in most cases altering the
level of the target protein. If there is greater availability of G pro-
tein inhibitors such as YM-254890 or alternative new tools, then it
will be interesting to determine if blocking a Gα protein results in
any changes in the level of other G proteins within the cell. Such
studies are currently underway in our laboratory.
PHARMACOLOGY OF Gαq INHIBITORS
YM-254890
The compound known as YM-254890, a cyclic depsipeptide iso-
lated from the Chromobacterium sp. QS3666, is a specific Gαq
inhibitor. YM-254890 has been shown to inhibit ADP-induced
platelet aggregation, which is mediated via GPCRs, P2Y1, and
P2Y12 (37). These receptors are associated with the Gαq and Gαi
signaling pathways, respectively. YM-254890 has no effect on the
P2Y12 signal transduction pathway, indicating that the compound
has some specificity for Gαq. It was also shown to inhibit Gαq-
coupled GPCR signaling by inhibiting calcium mobilization in
P2Y2-expressing C6-15 cells but not cAMP accumulation (38).
YM-254890 inhibits the signal transduction of Gαq by inhibit-
ing the exchange of GDP for GTP preventing the activation of
the G protein, rather than receptor-Gαq interactions (38). When
bound to GDP, the non-polar side chains of YM-254890 form
hydrogen bonds with the Switch I region; however, this is a con-
formation that cannot be maintained when bound with GTP (39).
Aside from antiplatelet activity, by electrically inducing carotid
artery thrombosis in rodents, YM-254890 was also shown to have
antithrombotic and thrombolytic effects (40).
YM-254890 was discovered and developed by Yamaguichi Phar-
maceuticals, Japan; Yamaguichi subsequently became the property
of Astellas Pharmaceuticals, Japan. YM-254890 was made available
to researchers 10 years ago and a small number of interesting stud-
ies were published. The initial results indicated that YM-254890
is a useful tool for investigating Gαq/11-coupled receptor signaling
and the physiological roles of Gαq/11. For example, Gαq knock-
out mice have lower blood pressure than appropriate controls
(41). This indicates some potential for a Gαq inhibitor to be an
anti-hypertensive agent and accordingly YM-254890 has not been
provided to researchers presumably because of such identified
commercial value. As discussed above, molecular approaches in
this area, for example, G protein knock down can lead to rebound
increases in other G proteins with unexpected results. Accord-
ingly, it is understood that a number of groups are undertaking
programs for the synthesis of compounds related to YM-254890
and it is likely that the availability of potent and specific Gαq/11
inhibitors would greatly expand activity and knowledge in this
area and answer important questions such as the role of Gαq/11 in
GPCR transactivation signaling of protein kinase receptors.
UBO-QIC/FR300359
FR300359, henceforth referred to as UBO–QIC, is also, like YM-
254890 a cyclic depsipeptide; it is isolated from the Ardisia cre-
nata sims plant (42). UBO-QIC is structurally very similar to
YM-254890 and not surprisingly shows similar pharmacological
activity. UBO-QIC inhibits platelet aggregation in rabbits in vitro
and causes dose-related hypotension in anesthetized normotensive
rodents, which is consistent with the effect on blood pressure in
Gαq knock down mice (41, 43). The blood pressure lowering effect
was attributed to the ability of UBO-QIC to partially mediate nitric
oxide release from endothelial cells and inhibit calcium migration
caused by voltage-dependent and receptor-operated channels (44).
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Since the discovery of UBO-QIC as a Gαq antagonist, there
have been limited studies showing its use. In HEK cells trans-
fected with TRPV4, PAR-2-mediated intracellular calcium release
was abolished by UBO-QIC when compared to control; how-
ever, extracellular calcium influx through the TRPV4 ion channel
was unaffected thus showing that PAR-2 coupling to TRPV4 is
not mediated by Gαq signaling (45). There have been no stud-
ies directly comparing the activity of YM-254890 and UBO-QIC
possibly because of the linked variability of the former com-
pound whereas at the time of preparing this review, UBO–QIC
is commercially available.
THE PEPTIDE ANTAGONIST GP-2A
In 2004, Tanski et al. (30) discovered a competitive Gαq inhibitor,
G Protein antagonist-2A, also known as GP-2A. GP-2A is a pep-
tide that selectively inhibits the action of Gαq by M1 muscarinic
cholinergic receptors. The signaling pathway of Gαq and its role in
cell proliferation with rat pulmonary artery smooth muscle cells
were studied. Angiotensin II-mediated proliferation, PLCβ acti-
vation, and Erk1/2 phosphorylation were inhibited by more than
50% in the presence of GP-2A (30). The EGFR can be activated
by EGF to generate an intracellular signaling pathway leading to
the phosphorylation of several downstream effector proteins such
as Erk1/2 (46). Tanski and colleagues have evaluated angiotensin
II (as specific Gαq agonist) to effectively reduce Erk1/2 activation
mediated by PLCβ via Gαq in the presence of GP-2A by showing its
association with the phosphorylation of Erk1/2 in rat pulmonary
artery smooth muscle cells (30). This study provides a strong foun-
dation for our laboratory research as we can further investigate the
possibility of this downstream signaling pathway to see whether
or not GP-2A can act on other GPCR agonists such as thrombin to
effectively respond similarly via Gαq in other smooth muscle cell
types such as human VSMCs.
OTHER PHARMACOLOGICAL TOOLS FOR EVALUATING THE
ROLE OF Gαq IN GPCR SIGNALING
It is also possible to indirectly assess the role of Gαq in GPCR
signaling by analyzing downstream events through the use of
inhibitors (Figure 2). For example, as detailed above GPCR ligand
engagement activates Gαq which in turn activates phospholipase
C leading to the catalysis of PIP2 and the release of DAG and IP3.
There are inhibitors of PLC–β including U73122, and its inactive
analog U-73343 is available to use as a control compound. These
compounds have been widely used (47–51) although they are not
considered to be especially useful and specific agents. The antibi-
otic, neomycin, can also be used as a PLCβ inhibitor in that it
binds to the target substrate, PIP2 and inhibits the action of PLCβ
to release DAG and IP3, which can be assessed as a reduction in
IP3 accumulation or increased free intracellular calcium (23). As
always with pharmacological approaches, it is likely that the use of
multiple approaches can provide the best information on the role
of Gαq in GPCR signaling (Table 1).
U73122 AND ITS INACTIVE ANALOG U-73343
To maximize our knowledge of Gαq, it is possible to examine the
downstream role of Gαq in GPCR by assessing the inhibitors of
PLC, U73122, and its inactive analog U73343. U73122 and its
analog U73343 were used to show the effect of human platelet
FIGURE 2 | Pharmacological agents to inhibit downstream signaling
intermediated of Gαq. Once GPCR is activated by its agonist, Gαq signaling
activates phospholipase C β (PLCβ), which leads to the hydrolysis of
phosphatidylinositol 4,5-biphosphate (PIP2) and diacylglycerol (DAG). The
former leads to initiate the release of 1,4,5-inositol tris phosphate (IP3)
initiating calcium release, activating protein tyrosine kinase 2 (PYK2), which
leads to proto-oncogene tyrosine protein kinase (Src) activating Ras guanine
nucleotide exchange factor (Ras GEF), which leads to the activation of MAPK
signaling. MAPK signaling pathway can also be downstream of DAG that
activates protein kinase C (PKC), which leads to the activation of MAPK
signaling. Gαq signaling can also go indirect of PLCβ by activating Rho GEF
leading to the activation of the Rho/ROCK signaling pathway.
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Table 1 | Pharmacological tools used as inhibitors of Gαq or its
downstream signaling intermediates.
Inhibitors Actions Reference
Direct YM-
254890
UBO-QIC
Gαq inhibitor by inhibiting the
exchange of GDP for GTP
preventing the activation of the
G protein
(37)
(42)
GP-2A Competitive Gαq inhibitor (30)
Downstream U73122/
U73343
PLC-β inhibitors (47)
Neomycin Binds to PIP2 and blocks the
action of PLC-β
(23)
BAPTA-
AM
A chelator of calcium ions
reventing increase in intracellular
calcium
(52)
Y-27632 RhoA/ROCK specific antagonist (53)
calcium signaling and protein tyrosine phosphorylation in the
presence of thrombin, collagen, and thapsigargin (47). U73122
showed complete inhibition of calcium signaling in the presence
of this agonist, which was generated via the activation of PLC
specifically the β and γ isoforms (47, 54). U73343 did not show
any calcium inhibitory effect via the activation of PLC but rather
showed the calcium inhibitory effect via the upstream activation
of cPLA2 in the presence of thapsigargin and collagen (47). This
provides a clear indication that U73343 has minimal activity as a
PLC inhibitor.
The study also investigated the role of Gαq in the transactivation
of PTK receptors to show that platelets, stimulated by thrombin
increased protein tyrosine phosphorylation. In the presence of
U73122, the phosphorylation of tyrosine kinase was abolished
(47). As mentioned earlier, Gαq are prominent in signaling in
VSMCs. From the recent study, it is possible that we can replicate
this investigation in other cell type to further study the PTK and
perhaps the serine/threonine kinase transactivation pathway in the
presence of U73122.
NEOMYCIN AND ITS POTENTIAL ROLE FOR Gαq SIGNALING
STUDIES
As mentioned above, another agent, which can further be investi-
gated, is neomycin, a PLC inhibitor. Our laboratory has previously
reported that neomycin strongly inhibits the formation of IP3
in rat aortic smooth muscle cells in the presence of endothelin,
an agonist that influences contraction in smooth muscle (23).
Endothelin acts via specific ET-A receptors, which are coupled
to PLC to stimulate calcium mobilization (23). ETR is coupled
to PLC via G proteins (55) and its activation acts on the car-
diac muscle where it binds to ryanodine located on the SR, which
releases calcium mobilization within the cardiac muscle cell (56).
As known, the signaling pathways of GPCRs through G proteins
contribute to various functions in different cell types such as the
contraction of blood vessels and are involved in many diseases
such as cancer and cardiovascular disease (16, 57). In unpub-
lished data, we have found that neomycin has a dose-dependent
inhibition of thrombin-mediated release of intracellular calcium
in human VSMCs. Further investigation is required to understand
its pharmacological signaling pathway via Gαq.
THE ACTION OF INTRACELLULAR CALCIUM ION TO STUDY
THE ROLE OF Gαq IN GPCR SIGNALING
The activities of calcium ions on the inhibitory action of calcium
channel blockers and its impact on atherogenesis in the regulation
of proteoglycan biosynthesis in human VSMCs was studied via
the role of ionomycin and bis (2-amionophenyl) ethyleneglycol-
N,N,N ′,N ′-tetraacetic acid, tetraacetoxymethyl ester (BAPTA-
AM) (58).
Ionomycin is a calcium ionophore, which elevates intracellular
calcium (58). Radioactive sulfate incorporation into proteogly-
cans was unaffected by ionomycin, providing support that calcium
regulation is not involved in proteoglycan synthesis (58).
Similarly, BAPTA-AM, a chelator of calcium ions, which pre-
vents an elevation of intracellular calcium by acting as a calcium
buffer (52) had no effect on proteoglycan synthesis (58). Ago-
nists, TGF-β, and ET-1 stimulated BAPTA-AM to decrease sulfate
incorporation into proteoglycans. The interpretation therefore
concluded that there were no effects on calcium ion stimula-
tion hence intracellular calcium does not play a role in VSMC
proteoglycan synthesis (58).
Y-27632 – A RhoA/ROCK INHIBITOR
Y-27632 is a widely used specific inhibitor of RhoA/ROCK fam-
ily of protein kinases (53). The ROCK family of kinases is
involved in Rho-induced formation of actin-stress fibers and focal
adhesion as well as the down-regulation of myosin light chain
(MLC) phosphatases. Deng et al. (59) examined the role of the
PLC calcium pathway and Rho Kinase in PAR-1-mediated CCL2
release. Rho kinase activation is mediated by a Gαq-PLC-calcium-
dependent PKC pathway to release thrombin-mediated CCL2.
Thrombin-induced phosphorylation of MLC was inhibited by
PLC calcium and calcium-dependent PKC inhibitors. Q94 a PAR-
1 selective Gαq antagonist abolished thrombin-mediated MLC
phosphorylation. Subsequent experiments showed that block-
ade of Rho kinase signaling is not essential for CCL2 pro-
tein production but is important in the release of CCL2 from
the cell, as thrombin-mediated CCL2 levels are inhibited by
Y-27632.
Having provided evidence that cytoskeletal rearrangement
is involved in thrombin-mediated transactivation of TGFBR1,
ROCK inhibitor Y-27632 was used to study the role of ROCK in the
transactivation signaling pathway. Y-27632 inhibited the down-
stream product of ROCK-phosphor-Ezrin, Radixin, and Moesin.
The ROCK inhibitor abolished the thrombin-mediated increase
in phosphoSmad2, indicating that Y-27632 inhibits the activity of
ROCK and ROCK is involved in the thrombin-mediated trans-
activation of TGFBR1. To evaluate the role of ROCK signaling
in cardiac contractility, hearts were treated with Y-27632. This
lead to a significant inhibition in the peak of pressure of non-
transfected hearts but no reduction in basal contractility in hearts
overexpressed withα1A-adrenergic receptor signifying that ROCK
pathways play an important physiological role in maintaining
baseline contractility (60).
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Gα GENE KNOCKDOWN USING siRNA
Despite the very large number of GPCRs, there are relatively few
studies that have used the potential of Gαq/11 gene knockdown
by siRNA to explore their roles in the signaling cascades. One
of the first reported gene knockdown studies of Gα proteins was
the knockdown of Gαq and Gα11 gene expression using siRNA
in HeLa cells (35). This work demonstrated an absolute require-
ment of Gαq/11 to stimulate histamine-mediated phospholipase C
activity. Silencing of Gαq or Gα11 caused indistinguishable pheno-
types, loss of half of histamine-stimulated PLC activity, despite the
fact that concentrations of Gα11 exceed those of Gαq by 10-fold.
No compensatory increases of either Gαq or Gα11 were observed
following loss of either protein. Loss of Gαq or Gα11 did cause
increased accumulation of Gαi and Gαo (35). A study character-
izing the Gα subunits required for PAR-1-mediated endothelial
cell permeability showed that both Gαq and Gα11 were necessary
for thrombin to increase permeability while the need for Gα12/13
was less. Both protein subunit families contributed significantly
to RhoA activation by thrombin (61). Knockdown of Gαq/11 in
human pulmonary artery smooth muscle cells alters but does
not prevent hypoxia-induced mitogenic factor-mediated calcium
release demonstrating that Gαq/11 contributes to hypoxia-induced
PLC signaling pathway (62). Using siRNA knockdown of Gαq or
Gαs in human prostate epithelial cells, GPCR melatonin receptor
MTNR1A has a dual requirement of Gαq and Gαs receptor cou-
pling for effective MTNR1A signal transduction (63). In HEK cells
expressing high levels of thyrotropin-releasing hormone receptor
2, knockdown of Gαq/11 reduces persistent agonist-induced sig-
naling by 82% and suggests that Gαq/11 is a required component
of the activated receptor signaling pathway (64). Clearly, there is
considerable scope to use siRNA technology more often as a very
useful tool in delineating the importance of Gα proteins in GPCR
signaling.
Gα KNOCKOUT MICE AND Gα PROTEIN MUTANTS AND
CHIMERAS
Other molecular approaches to investigate the varied roles of Gα
proteins include generating Gα protein knockout mice or overex-
pressing a variety of Gα mutants and chimeras in cell lines and
examining their effects in different cellular contexts.
Over the last decade, the most widely used Gα knockout model
is the Gαq/11 knockout mouse. Gαq/11-deficient fibroblasts from
these knockout mice have been used to study a large number of
GPCR signaling pathways. These studies have demonstrated that
Gαq/11-deficient mouse fibroblasts expressing bradykinin B (2)
receptor require both Gαi and Gαq/11 for effective bradykinin-
mediated stimulation of the Erk cascade (65). Gαq/11 knockout
mouse fibroblasts expressing GPCR α1b-adrenoreceptor protein
or fusion proteins consisting of the α1b-adrenoreceptor and wild-
type Gαq/11 or palmitolyation-resistant Gαq/11 mutants reveal
agonist-mediated receptor/Gαq/11-coordinated release of the βγ
complex (66). Expressing fusion proteins consisting of the GPCR
α1b-adrenoreceptor with various Gα mutants results in altered
receptor contact domain residues and enables the identification of
key agonist and antagonist receptor contact sites that are necessary
for α1b-adrenoreceptor activation. An aromatic group four amino
acids before the carboxy terminus in Gαq/11 provides maximal
α1b-adrenoreceptor activation information (67). Mouse embry-
onic fibroblasts from double knockout Gαq/11 and β-arrestin mice
demonstrated that kisspeptin activation of GPCR 54 regulates
the hypothalamic–pituitary–gonadal axis in reproductive func-
tion and that GPCR 54 has a co-dependency of both the Gαq/11
and β-arrestin pathways in a time-dependent manner to regulate
Erk and localize pErk to the nucleus for downstream gene expres-
sion (68). Knock-in of ETR type A or type B in Gαq/11-deficient
mice showed differential craniofacial development is based on spe-
cific ETR Gαq and Gαq/11 requirements (69). Clearly, the Gαq/11
knockout mouse has proven itself a reliable and useful tool in the
study of Gα protein-mediated signaling.
An alternative approach to exploring Gα protein signals has
been to co-express Gα protein mutants or chimeras in different
cell types. Gαq chimeric mutants containing Gαi or Gαo tails co-
expressed in COS-7 cells with opioid receptors and stimulated
with opioid agonist are insensitive to pertussis toxin catalyzed
ADP-ribosylation demonstrating an inability of Gαi or Gαo tails to
serve as pertussis toxin substrates (70). Gi-coupled opioid recep-
tors increase Gαq signals as demonstrated by the co-expression
of constitutively active Gα mutants in COS-7 cells and requires
activated phospholipase beta and Gβγ dimers (71).
A considerable number of studies have explored membrane
localization of Gα proteins in different cellular contexts and
described a diversity of requirements. N-terminal sequence-
mutated Gα proteins expressed in HEK293 cells are unable to
localize to the plasma membrane due to their inability to bind
to Gβγ or attach myristate and palmitate (72). Mutated Gαq and
Gαs proteins deficient in Gβγ-binding and co-expressed with dif-
ferent β(1–5) or γ2/3 subunits show that Gβγ and Gα proteins
promote membrane localization of the other and requires palmi-
toylation (73). Defects in plasma membrane localization of Gαs
occur when four N-terminal basic residues are mutated to gluta-
mine; however, mutation of nine basic residues in Gαq is required.
Gβγ co-expression partially rescues localization indicating that
the characteristics of the N-terminal residues of Gαs and Gαq are
critical in membrane localization of these proteins (74). Using
co-expressed constitutively active Gαq or Gαq/12, the activation
of ETRs was shown to mediate the binding of Gαq or Gαq/12 in
caveolae to enable the downstream activation of Erk1/2 (75).
Gα protein-mediated signaling studies across a wide variety
of GPCRs dominate the literature using Gα protein mutants or
chimeras. Constitutively active Gαq, Gαq12, or Gαq13 mutants
transfected into Jurkat cells co-expressing GPCR muscarinic
cholinergic receptor subtypes demonstrated a requirement for
Gαq13 to activate downstream transcription factor serum response
factor. However, the M1 subtype also required Gαq/11 and calcium
when regulator proteins RGS2 and RGS4 were co-transfected that
demonstrates a unique pathway for the M1 receptor (76). Gαq/11
(Y356D) mutation results in altered GPCR α1B-adrenoreceptor
contact domain and abolishes receptor function, however, does
not affect ligand binding (67). Studies using constitutively active
mutants Gαq (Q209L) and Gαq/13 (Q226L) demonstrate that Gαq
activates rat brain phospholipase D1; however, Gαq/13 inhibits its
activity (77). Gαq deletion mutants were used to demonstrate that
Gαq mediates down-regulation of the vesicle-associated GPCR
vesicular monoamine transmitter transporter VMAT2 activity in
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platelets (78). Expression of a constitutively active Gαq (R183C)
mutant inhibited the expression of ezrin–radixin–moesin-binding
phosphoprotein 50 and subsequent internalization of GPCR
thromboxane A(2) beta receptor independently of PLC and PKC
pathways (79). Specific Gα peptides and dominant negative Gα
mutants were used to demonstrate the ability of α-thrombin to
activate different effectors via Gα, Gβγ, and Gαi2, respectively, in
Chinese hamster embryonic fibroblasts and thereby regulate the
activation of the PI3kinase/Akt pathway (80). Molecular model-
ing and testing GST–fusion proteins of Gαq mutants–GPCR kinase
complexes revealed a critical residue Gαq Pro185 at the interface
with GPCR kinase 2 with residues Gαq K77, L78, Q81, and R92
also playing key interactive roles (81). Constitutively active Gαq,
Gαq/12, and Gαq/13 overexpressed in human astrocytoma cells
increased agonist-activated thromboxane A2 receptor-mediated
IL-6 production while mutated Gαq and Gαq/13 overexpression
blocks IL-6 production (82). Using both constitutively active and
dominant negative Gαq subunit expression showed that in neu-
roblastoma cells Gαq elicits a rapid signal at the plasma membrane
(83). Expression of constitutively active Gαq (Q209L) mutant
inhibits Ras and the PI3K/Akt pathway; however, minimal effects
are seen on the Ras/Raf/MEK/Erk signaling pathway (84). Gαq
mutants that cannot bind Gβγ are unable to be stimulated by the
mitogenic Pasteurellosis multocida toxin (PMT) demonstrating
the requirement of cohesive Gαq/Gβγ signaling for this toxin acti-
vation pathway (85). Expressing GTPase-deficient Gαq mutant
in the human adrenal cell line H295R depolarizes the two-pore
loop potassium channel TASK and thereby increases aldosterone
secretion (86). Chimeric G proteins have been used to determine
Gα responses from orphan GPCRs with unknown Gα coupling
partners. A luciferase reporter system with a chimera that con-
tains promoter elements that drive Gs, Gq, and G12 signals and
another chimera with promoters to drive Gi signals revealed neu-
romedin U receptor 1 activating Gq, neuromedin U receptor 2
activating Gi, and luteinizing hormone receptor activating Gq and
Gs proteins (87).
POTENTIAL OF Gαq AS A THERAPEUTIC TARGET
Gαq as a protein has several functions, which are valuable ther-
apeutically. The GTPase activity, which hydrolyzes bound GTP
to GDP, is an enzyme action that can be targeted. The binding
of GDP and GTP are potential targets in the same manner in
which the ATP binding site is target of many drugs inhibiting
kinases (88). The ligand-activated GPCR acts as a GEF, which
stimulates the exchange of GDP for GTP on the Gα peptide and
this could be targeted. Furthermore, the protein contains a switch
mechanism and this can be targeted as it is the target of the
YM class of inhibitors (39). So, it is both theoretically possible
and has been demonstrated that Gαq can be exploited as a drug
target.
The consequences of targeting signaling molecules have the-
oretical limitations based on the role of such targets in nor-
mal physiology but also conceptually there may be situations,
pathophysiology, in which the activity of Gαq is elevated or
enhanced and presents itself as a target. Such situations are com-
mon in therapeutics but in most cases can only be established
experimentally.
As discussed above, inhibition of Gαq/11 using YM-254890
has demonstrated anti-platelet aggregation, antithrombotic, and
thrombolytic properties in a rat model of carotid artery throm-
bosis (40). Therefore, compounds that inhibit Gαq/11 could show
enormous potential in the treatment of thrombotic conditions
such as thrombotic stroke and myocardial infarction in humans.
Additionally, a number of recent studies have also implicated a
role for Gαq/11 in a range of metabolic conditions such as obesity
and type 2 diabetes (89, 90). Activation of Gαq results in pro-
nounced increases in blood glucose levels in a mouse model (89),
thus, compounds that inhibit Gαq could also show promise as a
future treatment option for type 2 diabetes.
In the important cardiovascular context of hypertension, Gαq
knockout mice have reduced blood pressure (41) and YM-
254890 has demonstrated some anti-hypertensive properties (40).
Although there are many effective anti-hypertensive agents cur-
rently available, there are also many subjects with medication-
resistant hypertension, which does require a niche for new thera-
pies although it is unclear if a Gαq/11 inhibitor would be suitable
to consider for such a niche.
CONCLUSION
G protein coupled receptor signaling is a major area of cell biology
and therapeutics. The functioning of the seven transmembrane
GPCR has been one of the most intensively studied areas of pro-
tein function. GPCRs signal through G proteins of the α and βγ
subtypes where most of the signaling specificity is determined by
the Gα protein. For the Gαprotein family, these signaling pathways
include the well-known PLC, PKC, and IP3 pathways and the lesser
appreciated Rho/ROCK pathway. For multiple reasons, mostly the
limited availability of pharmacological agents, which inhibit G
protein function, the role of G proteins in GPCR signaling has been
severely under-studied relative to the intense activity around the
GPCRs. This is true for the Gαq proteins, which are the subject of
this review but also for other G proteins. Given the broad involve-
ment of GPCRs in cellular functioning, this is a major deficit
in cellular signaling studies and potentially more importantly in
the search for new drug targets. The recently expanding area of
GPCR signaling is that of transactivation-dependent signaling in
which GPCR transactivation of protein tyrosine and protein ser-
ine/threonine kinase cell surface receptors enormously expands
the range of activities associated with the respective GPCRs. The
potential role of G proteins and Gα proteins in particular in GPCR
transactivation signaling is one very interesting area to be explored.
It is likely that there are programs of chemical synthesis underway
to synthesize inhibitors of Gαq proteins and these will increase the
availability of inhibitors and also with the importance of this area
hopefully lead to new studies, which produce a range of agents,
some of which may be useful in in vivo studies. It is hoped that
such studies may provide insights into the potential role of Gαq
in disease processes and reveal the extent to which such inhibitors
may represent novel therapeutic agents in a range of conditions
from cancer to cardiovascular disease.
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